|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, prophylactic or therapeutic application of iSP-D decreased weight loss and reduced viral lung titers in a murine model of IAV infection using a clinical isolate of H1N1pdm09 virus.
|
31749796 |
2019 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Role and Molecular Mechanism of Action of Surfactant Protein D in Innate Host Defense Against Influenza A Virus.
|
29951070 |
2018 |
|
Influenza A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Surfactant protein D (SP-D) is expressed in the mucosal secretion of the lung and contributes to the innate host defense against a variety of pathogens, including influenza A virus (IAV).
|
30105014 |
2018 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
IAV hemagglutination inhibition, IAV aggregation, and neutralization of IAV infection studies showed that RpNCRD, unlike the human analogue RhNCRD, exhibits potent neutralizing activity against pandemic A/Aichi/68 (H3N2), enabled by both porcine-specific structural features of its CRD.
|
29769321 |
2018 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surfactant protein (SP)-D is the major neutralizing inhibitor of IAV in mouse airway fluids and SP-D-resistant IAV mutants show enhanced virus replication and virulence in mice.
|
27110707 |
2016 |
|
Influenza A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mutations flanking the carbohydrate binding site of surfactant protein D confer antiviral activity for pandemic influenza A viruses.
|
24705721 |
2014 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other proteins of the innate immune system, namely human surfactant protein A and porcine surfactant protein D, have been reported to express sialylated glycans which facilitate inhibition of particular IAV strains, yet the specific viral determinants for recognition of these inhibitors have not been defined.
|
23544079 |
2013 |
|
Influenza A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Introduction of N-linked glycans in the lectin domain of surfactant protein D: impact on interactions with influenza A viruses.
|
21489996 |
2011 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oligosaccharides on the hemagglutinin (HA) and neuraminidase of influenza A virus (IAV) are a target for recognition by lectins of the innate immune system, including soluble surfactant protein-D and the macrophage mannose receptor on airway macrophages.
|
21768397 |
2011 |
|
Influenza A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although native human SP-D shows potent antiviral and aggregating activity, trimeric recombinant neck+CRDs (NCRDs) show little or no capacity to influence IAV infection.
|
21965658 |
2011 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surfactant protein D (SP-D) plays important roles in innate defense against respiratory viruses [including influenza A viruses (IAVs)].
|
20375547 |
2010 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surfactant protein D (SP-D) plays important roles in the initial innate defense against influenza A virus (IAV).
|
19017984 |
2008 |
|
Influenza A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These studies indicate that a common human polymorphic form of SP-D may modulate host defense against IAV and give impetus to clinical studies correlating this genotype with risk for IAV infection in susceptible groups.
|
17280604 |
2007 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
SP-D from both peaks bound to mannan-coated ELISA plates.SP-D from the high m.w. peak bound preferentially to intact influenza A virus and Gram-positive and Gram-negative bacteria, whereas the monomeric species preferentially bound to isolated LPS.
|
15661913 |
2005 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since most strains of IAV currently circulating are glycosylated at N165, SP-D may play a role in protection from IAV infection.
|
15280465 |
2004 |